Comparative Pharmacology
Head-to-head clinical analysis: ANGIOTENSIN LL ACETATE versus EPHEDRINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOTENSIN LL ACETATE versus EPHEDRINE SULFATE.
ANGIOTENSIN ll ACETATE vs EPHEDRINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin II acetate is a synthetic peptide that acts as a potent vasoconstrictor by binding to the angiotensin II type 1 (AT1) receptor on vascular smooth muscle cells, leading to increased intracellular calcium and smooth muscle contraction. It also stimulates aldosterone secretion from the adrenal cortex, promoting sodium and water retention.
Ephedrine sulfate is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors and indirectly stimulates norepinephrine release from sympathetic neurons, leading to vasoconstriction, bronchodilation, and increased heart rate and contractility.
Intravenous infusion: 1-40 ng/kg/min titrated to achieve target blood pressure. Initial rate: 10 ng/kg/min.
50 mg orally every 3-4 hours as needed; 25-50 mg intramuscularly or subcutaneously every 3-4 hours; 5-25 mg intravenously slowly every 5-10 minutes as needed, not to exceed 150 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 30-60 minutes; clinical effect is short-lived requiring continuous intravenous infusion.
Terminal elimination half-life 3-6 hours in adults with normal renal function; prolonged in renal impairment or alkaline urine.
Primarily renal (90-100%) as unchanged drug; minimal biliary/fecal elimination (<10%).
Renal excretion of unchanged drug (60-70%) and minor metabolites; small amount biliary; pH-dependent; acidic urine enhances elimination.
Category C
Category C
Vasopressor
Vasopressor